Investment
Features
FeesSafety
Academy
More
Pluang+

Oura's IPO aims to raise $2.2B, mostly benefiting existing investors, with limited funds for the company itself.

Company Fundamentals
21 Sep 2026
TechCrunch
View Source
Neutral
Oura's IPO aims to raise $2.2B, mostly benefiting existing investors, with limited funds for the company itself.

Oura, the smart ring maker, plans to raise up to $2.2 billion in its IPO by offering 50 million shares priced between $40 and $44. However, nearly two-thirds of the shares sold are from existing shareholders, mainly Forerunner Ventures, who will gain about $1.2 billion, while the company itself will net around $567 million before fees. Most of Oura's proceeds will be used to pay off tax obligations related to employee share grants, leaving only about $6.2 million for general use. The IPO primarily serves as an exit for early investors rather than a major fundraising event, while Oura continues to grow rapidly, especially in its profitable subscription business, which now accounts for 20% of revenue.

Oura's $2.2 billion IPO is the subject here, provided as context for readers. For those following the Technology sector, Pluang data as of Sep 21, 2026 23:33 WIB shows 129 of 150 US tech stocks rose today. Notably, AXTI gained 12.94% to USD 79.09 with a typical hold time of 16 days, AKAM increased 10.82% to USD 115.83 with 48 days typical hold, and VNET rose 10.28% to USD 7.19 with a 15-day hold time.

More News

Boeing faces 737 MAX production delays but analysts see potential 32% stock upside.

Boeing faces 737 MAX production delays but analysts see potential 32% stock upside.

Boeing is experiencing ongoing production challenges with its 737 MAX aircraft, causing delays and a recent 3.7% stock drop. Jefferies lowered its price target to $265, still implying a 32% upside from current prices, reflecting cautious optimism. Ba...

Analyst Insights
Neutral
38 minutes ago
Alkermes' ALKS7290 shows strong early results in ADHD treatment, boosting stock by 2.3%.

Alkermes' ALKS7290 shows strong early results in ADHD treatment, boosting stock by 2.3%.

Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...

Market News
Bullish
3 hours ago
BrandPilot AI to attend Marketecture Live 2026, focusing on AI and transparency in digital advertising.

BrandPilot AI to attend Marketecture Live 2026, focusing on AI and transparency in digital advertising.

BrandPilot AI announced its participation in Marketecture Live 2026 in Chicago, an event that gathers advertising, media, and technology professionals to discuss industry developments. The company aims to engage in discussions about artificial intell...

Market News
Neutral
4 hours ago
Meta shares jump 12% on strong early adoption of Muse AI assistant and higher price target

Meta shares jump 12% on strong early adoption of Muse AI assistant and higher price target

Meta Platforms shares surged 12% to $747.91 following early success of its new Muse AI assistant, which topped Apple's US App Store with over 730,000 downloads shortly after launch. Wells Fargo raised Meta's price target to $796, citing strong moment...

Market News
Bullish
4 hours ago
Ventas posts strong Q2 2026 growth, raises full-year guidance on senior housing strength.

Ventas posts strong Q2 2026 growth, raises full-year guidance on senior housing strength.

Ventas reported solid Q2 2026 results with 10% same-store cash NOI growth and 9% normalized FFO/share growth, driven by its dominant senior housing portfolio. Management raised its 2026 FFO/share guidance and acquisition targets, citing a strong bala...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App